Arcus Biosciences, Inc. (NYSE:RCUS), today reported financial results for the first quarter ended March 31, 2022 and provided a pipeline update on its six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a and PD-1 across multiple common cancers.
May 9, 2022
· 16 min read